The first of its kind to enter the clinic, sabirnetug, an immunotherapy drug candidate, is designed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration, sabirnetug addresses an underlying cause of Alzheimer’s disease by preventing toxic AβOs from binding to dendritic spines and helping preserve neuronal function.
OUR PROGRAMS
Sabirnetug (ACU193)
Our sabirnetug (ACU193) program is focused on selectively targeting toxic soluble amyloid beta oligomers (AβOs), which are believed to be an early and persistent driver of Alzheimer’s disease pathology. As a monoclonal antibody designed to preferentially bind these neurotoxic species, sabirnetug aims to prevent their interaction with neurons and preserve synaptic function. Clinical data to date have demonstrated central nervous system penetration, target engagement, and a favorable safety profile, supporting its continued development in early Alzheimer’s disease. Through sabirnetug, we are advancing development of a differentiated therapeutic approach that addresses a key upstream mechanism of neurodegeneration with the potential to deliver disease-modifying and symptomatic benefits for patients.
Enhanced Brain Delivery™ (EBD®)
Our EBD program combines an oligomer targeted antibody with a validated blood brain barrier (BBB) carrier technology.Acumen is collaborating with JCR Pharmaceuticals, to incorporate their transferrin receptor (TfR)-mediated brain delivery, J-Brain Cargo® into our program. The first drug developed based on this technology is IZCARGO™ (INN: pabinafusp alfa) and is approved in Japan for the treatment of Hunter syndrome, a lysosomal storage disorder. By applying EBD technology to next-generation candidates, we aim to further advance our mission of developing innovative therapies for Alzheimer’s disease.
OUR CLINICAL TRIALS
ALTITUDE-AD
NCT identifier NCT06335173
This ongoing study is a Phase 2, global, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenous sabirnetug (ACU193) in early Alzheimer’s disease.
INTERCEPT-AD
NCT identifier NCT04931459
This completed study was a Phase 1, U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and tolerability, and to establish the clinical proof of mechanism, of sabirnetug (ACU193) in early Alzheimer’s disease.
